Health officials are warning people who were at UCHealth Medical Center of the Rockies in Loveland on March 17-18 of ...

Governor Maura Healey on Thursday unveiled a new public health measure aimed at taming a growing public health threat: Alpha-gal syndrome, the red-meat allergy triggered by the bi ...

This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.

Learn how KMA and LMA represent a breakthrough in treatment approaches for multiple myeloma and related disorders.

Chronic pancreatitis is now recognized as a complex fibroinflammatory disorder involving genetic, environmental, and ...

Someday soon, doctors who don’t run their patients’ records through an AI model will be considered negligent. At least, that’s what Steve Brown thinks. He’s the founder of CureWise, an app designed to ...

An AI model that screens ionizable lipids by 3D conformation identified a candidate 14.8 times more efficient than current ...

Immunovant begins new coverage by Sanford C. Bernstein, bringing renewed market attention to its clinical-stage developments. Rating distribution across firms reflects varied perspectives on valuation ...

Hematochezia was the most common symptom in patients with AAV and GI manifestations, and other symptoms included abdominal pain, fever, diarrhea, and vomiting.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...

True IgE-mediated local anesthetic hypersensitivity is <1% of reported reactions, so risk reduction should prioritize preservative-free amide selection, minimal effective dosing, and strict avoidance ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...